Hess KR - Search Results

1

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Varadhachary GR, et al. Among authors: hess kr. J Clin Oncol. 2008 Sep 20;26(27):4442-8. doi: 10.1200/JCO.2007.14.4378. J Clin Oncol. 2008. PMID: 18802157

2

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Abbruzzese JL, et al. Among authors: hess kr. J Clin Oncol. 1995 Aug;13(8):2094-103. doi: 10.1200/JCO.1995.13.8.2094. J Clin Oncol. 1995. PMID: 7636553

3

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.

Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Abbruzzese JL, et al. Among authors: hess kr. J Clin Oncol. 1994 Jun;12(6):1272-80. doi: 10.1200/JCO.1994.12.6.1272. J Clin Oncol. 1994. PMID: 8201389

4

Are time or intensity factors important to the definition of metastases of unknown origin?

Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Abbruzzese JL, et al. Among authors: hess kr. J Natl Cancer Inst. 1996 Apr 3;88(7):462-3. doi: 10.1093/jnci/88.7.462-a. J Natl Cancer Inst. 1996. PMID: 8618241 No abstract available.

5

TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.

Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, Jaeckle KA, Levin VA. Kaba SE, et al. J Clin Oncol. 1997 Mar;15(3):1063-70. doi: 10.1200/JCO.1997.15.3.1063. J Clin Oncol. 1997. PMID: 9060546 Clinical Trial.

6

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Lenzi R, et al. Among authors: hess kr. J Clin Oncol. 1997 May;15(5):2056-66. doi: 10.1200/JCO.1997.15.5.2056. J Clin Oncol. 1997. PMID: 9164218

7

Unknown primary tumors metastatic to liver.

Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Ayoub JP, et al. Among authors: hess kr. J Clin Oncol. 1998 Jun;16(6):2105-12. doi: 10.1200/JCO.1998.16.6.2105. J Clin Oncol. 1998. PMID: 9626210

8

p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.

Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, Cleary KR, Skibber JM. Spitz FR, et al. Among authors: hess k. Clin Cancer Res. 1997 Oct;3(10):1685-90. Clin Cancer Res. 1997. PMID: 9815551

9

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.

Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN. Abbruzzese JL, et al. Among authors: hess kr. Clin Cancer Res. 1996 Sep;2(9):1489-97. Clin Cancer Res. 1996. PMID: 9816325 Clinical Trial.

10

Prognostic factors in resectable pancreatic cancer: p53 and bcl-2.

Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Hallin PA, Chiao PJ, Abbruzzese JL, Evans DB. Bold RJ, et al. Among authors: hess kr. J Gastrointest Surg. 1999 May-Jun;3(3):263-77. doi: 10.1016/s1091-255x(99)80068-7. J Gastrointest Surg. 1999. PMID: 10481119

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

419 results

Search Page

Filters